BridgeBio Pharma (BBIO) Competitors $26.49 +0.28 (+1.07%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BBIO vs. TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, SRPT, CTLT, and PCVXShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Sarepta Therapeutics Catalent Vaxcyte BridgeBio Pharma (NASDAQ:BBIO) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Is BBIO or TEVA more profitable? Teva Pharmaceutical Industries has a net margin of -5.73% compared to BridgeBio Pharma's net margin of -201.53%. Teva Pharmaceutical Industries' return on equity of 42.92% beat BridgeBio Pharma's return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-201.53% N/A -74.34% Teva Pharmaceutical Industries -5.73%42.92%7.25% Do insiders and institutionals believe in BBIO or TEVA? 99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher valuation and earnings, BBIO or TEVA? Teva Pharmaceutical Industries has higher revenue and earnings than BridgeBio Pharma. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$217.77M22.99-$643.20M-$2.41-10.99Teva Pharmaceutical Industries$16.77B1.49-$559M-$0.85-25.99 Do analysts prefer BBIO or TEVA? BridgeBio Pharma currently has a consensus price target of $47.69, indicating a potential upside of 80.04%. Teva Pharmaceutical Industries has a consensus price target of $20.88, indicating a potential downside of 5.50%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.86Teva Pharmaceutical Industries 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community believe in BBIO or TEVA? Teva Pharmaceutical Industries received 1160 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. However, 71.06% of users gave BridgeBio Pharma an outperform vote while only 67.81% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes16771.06% Underperform Votes6828.94% Teva Pharmaceutical IndustriesOutperform Votes132767.81% Underperform Votes63032.19% Does the media prefer BBIO or TEVA? In the previous week, Teva Pharmaceutical Industries had 18 more articles in the media than BridgeBio Pharma. MarketBeat recorded 27 mentions for Teva Pharmaceutical Industries and 9 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.90 beat Teva Pharmaceutical Industries' score of 0.54 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 10 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, BBIO or TEVA? BridgeBio Pharma has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. SummaryBridgeBio Pharma beats Teva Pharmaceutical Industries on 10 of the 18 factors compared between the two stocks. Ad MyBankTrackerYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.View the best savings account rates here Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.01B$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-10.9910.5989.9717.17Price / Sales22.99196.061,117.23117.03Price / CashN/A57.1643.0437.86Price / Book-3.435.094.784.78Net Income-$643.20M$151.83M$120.31M$225.60M7 Day Performance-3.64%-2.13%-1.92%-1.23%1 Month Performance13.11%-4.55%13.64%0.46%1 Year Performance-35.48%8.87%28.32%15.25% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.6915 of 5 stars$26.49+1.1%$47.69+80.0%-31.7%$5.01B$217.77M-10.99400Positive NewsHigh Trading VolumeTEVATeva Pharmaceutical Industries1.8708 of 5 stars$16.77+1.6%$19.67+17.3%+108.5%$19.00B$16.77B-19.7937,851Analyst DowngradeOptions VolumeNews CoverageBGNEBeiGene2.6104 of 5 stars$176.95-1.3%$253.69+43.4%-0.3%$17.24B$2.46B-21.7710,600MRNAModerna4.2751 of 5 stars$41.63-0.5%$79.50+91.0%-56.8%$16.02B$5.06B-7.195,600Analyst DowngradeVTRSViatris1.8728 of 5 stars$12.74+0.9%$13.67+7.3%+17.6%$15.21B$15.05B-17.0738,000News CoverageSMMTSummit Therapeutics3.2752 of 5 stars$18.21+2.1%$33.33+83.0%+650.8%$13.43B$700,000.00-63.68105News CoverageGap DownGMABGenmab A/S4.2467 of 5 stars$20.21+0.2%$45.20+123.7%-34.6%$13.37B$19.84B19.582,204High Trading VolumeRDYDr. Reddy's Laboratories1.8125 of 5 stars$14.76+2.1%$17.00+15.2%+15.1%$12.32B$299.87B22.9527,048Analyst DowngradeNews CoverageSRPTSarepta Therapeutics4.8184 of 5 stars$127.00+2.7%$178.71+40.7%+31.1%$12.13B$1.64B98.971,314Analyst ForecastPositive NewsCTLTCatalent2.7663 of 5 stars$63.47+0.6%$63.40-0.1%N/A$11.52B$4.38B-27.9116,900High Trading VolumePCVXVaxcyte1.5846 of 5 stars$90.74+3.4%$147.50+62.6%+45.8%$11.31BN/A-19.07160Analyst ForecastInsider TradeNews Coverage Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Moderna Alternatives Viatris Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Sarepta Therapeutics Alternatives Catalent Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BBIO) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
